Showing posts with label spain. Show all posts
Showing posts with label spain. Show all posts

Friday, August 28, 2026

Seasonal #surveillance in #humans in 2026 for #WNV #infection (ECDC, August 28 '26): 877 cases so far, of which 428 in #Italy

 


{Summary}

Week 35, 2026 | Produced on 27 August 2026 at 12:45, based on data submitted up until and including 26 August 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 26 August, 124 areas affected by West Nile virus (WNV) have been identified in 15 countries across Europe.

    ° These areas are located in: 

        § Italy (55), 

        § Greece (17), 

        § Romania (15), 

        § France (13), 

        § Serbia (six), 

        § Spain (four), 

        § North Macedonia (three), 

        § Croatia (two), 

        § Germany (two), 

        § Albania (one), 

        § Austria (one), 

        § Cyprus (one), 

        § Hungary (one), 

        § Kosovo* (one) and 

        § the Netherlands (one).

    ° This week, 25 areas are reported as affected for the first time this season. (...).

    ° The 15 countries have reported 877 locally acquired human cases of WNV infection: 

        § Italy (428 cases), 

        § Greece (222 cases, of which eight with unknown place of infection), 

        § Spain (79 cases), 

        § North Macedonia (49 cases), 

        § Romania (45 cases), 

        § France (28 cases), 

        § Serbia (11 cases), 

        § Croatia (three cases), 

        § the Netherlands (three cases), 

        § Austria (two cases), 

        § Cyprus (two cases), 

        § Germany (two cases), 

        § Albania (one case), 

        § Hungary (one case) and 

        § Kosovo* (one case)

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Friday, August 21, 2026

#Surveillance in #humans in 2026 for #WNV - Weekly #Report (ECDC, August 21 '26): 625 cases so far, of which 311 in #Italy

 


{Week 34 / 2026 - Summary}


Current situation

    Since the beginning of the 2026 transmission season, and as at 21 August, 99 areas affected by West Nile virus (WNV) have been identified in 12 countries across Europe.

    These areas are located in: 

        ° Italy (46), 

        ° Greece (17), 

        ° Romania (14), 

        ° France (eight), 

        ° North Macedonia (three), 

        ° Serbia (three), 

        ° Spain (three), 

        ° Albania (one), 

        ° Austria (one), 

        ° Germany (one), 

        ° Kosovo* (one) and 

        ° the Netherlands (one).


    This week, 21 areas are reported as affected for the first time this season. (...)

    The 12 countries have reported 625 locally acquired human cases of WNV infection: 

        ° Italy (311 cases), 

        ° Greece (157, of which seven with unknown place of infection), 

        ° Spain (63 cases), 

        ° North Macedonia (37 cases), 

        ° Romania (28 cases), 

        ° France (17 cases), 

        ° Serbia (six cases), 

        ° the Netherlands (two cases), 

        ° Albania (one case), 

        ° Austria (one case), 

        ° Germany (one case) and 

        ° Kosovo* (one case)

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Friday, August 14, 2026

Seasonal #surveillance in #humans in 2026 for #WNV - Weekly Update (ECDC, August 14 '26): 429 cases so far, of which 224 in #Italy

 


{Summary}

Week 33, 2026 Produced on 14 August 2026 at 06:00, based on data submitted up until and including 13 August 2026.


Current situation

    Since the beginning of the 2026 transmission season, and as at 13 August, 77 areas affected by West Nile virus (WNV) have been identified in nine countries across Europe.

    These areas are located in 

        § Italy (40), 

        § Greece (13), 

        § Romania (12), 

        § France (four), 

        § North Macedonia (three), 

        § Spain (two), 

        § Germany (one), 

        § Kosovo* (one) and 

        § Serbia (one).

    This week, 19 areas are reported as affected for the first time this season. (...)

    The nine countries have reported 429 locally acquired human cases of WNV infection: 

        § Italy has reported 224

        § Greece 105

        § Spain 42

        § North Macedonia 30

        § Romania 18

        § France six

        § Serbia two

        § Germany one and 

        § Kosovo* one case.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Wednesday, August 12, 2026

Seasonal #surveillance in #humans and #animals in 2026 for #WNV, Monthly Report (ECDC, August 12 '26): 245 cases so far

 


August 2026 | Produced on 12 August 2026 at 12:00 based on data submitted up until and including 5 August 2026


Epidemiological summary

Findings from human surveillance

    In 2026, and as at 5 August, seven countries in Europe have reported 245 locally acquired {1} human cases of West Nile Virus (WNV) infection. 

    The earliest and latest date of onset were on 12 May 2026 and 1 August 2026, respectively. 

    Locally acquired cases have been reported by Italy (139 cases), Greece (65, of which four with unknown place of infection), Spain (17 cases), North Macedonia (13 cases), Romania (six cases), France (four cases) and Germany (one case). 

    In Europe, 12 deaths have been reported by Greece (six deaths), Italy (five deaths) and Romania (one death).

    The number of human cases reported so far (245 cases) is below the average for the corresponding period over the past decade (403 cases). 

    However, reporting delays may result in an under-estimation of the current burden, as the 2026 data remain provisional, whereas the ten-year average is based on consolidated data from previous years. 

    In addition, this ten-year average is influenced by several particularly intense WNV transmission seasons, notably in 2018 (1 065 cases reported up to the corresponding week), 2022 (781 cases) and 2024 (654 cases).

    To date, most cases have been reported in Italy (139 cases) and Greece (65 cases). 

    Although the number of cases reported in Italy is lower than during the same period in 2025 (168 cases), it remains the most affected country in Europe in 2026. 

    Greece has reported more cases in 2026 than during the same period in 2025 (65 cases compared with 26 cases). 

    WNV circulation is currently most intense in the Attica NUTS 2 region (48 cases), with Anatoliki Attiki (East Attica, 34 cases) and Voreios Tomeas Athinon (North Athens, seven cases) most affected.

    As at 5 August 2026, locally acquired human cases of WNV infection had been reported in 58 NUTS 3 regions across seven countries

    This is higher than at the same point in 2025, when cases were reported in 40 NUTS 3 regions across six countries. 

    However, the geographical spread observed so far in 2026 remains well below the final extent recorded in recent seasons: by the end of 2025, affected regions numbered 160 and in 2024 there were 218. 

    The 2024 season remains the largest WNV season on record in terms of geographical spread.

    This year, six regions reported locally acquired human cases of WNV infection for the first time ever: France in PyrĂ©nĂ©es-Orientales (FRJ15); Germany in Rhein-Pfalz-Kreis (DEB3I); Italy in Campobasso (ITF22) and Viterbo (ITI41); North Macedonia in Pelagoniski (MK005) and Vardarski (MK001).

    Similar to previous years, most cases were reported among males aged 65 years and above

    Most cases were hospitalised (72%) and presented with neurological symptoms (58%). 

    The proportion hospitalised was lower than the average reported during the previous decade (87%), while the proportion with neurological symptoms was also slightly lower than the historical 10-year average (64%). 

    The case fatality rate was approximately 5%, lower than the average reported during the previous decade (11%). 

    However, this estimate should be interpreted with caution, as clinical outcomes may not yet be known for all reported cases and additional deaths may be recorded as the season progresses and data are consolidated.

    Owing to delays in diagnosis and reporting, and because most WNV infections are asymptomatic or subclinical, the reported case numbers probably underestimate the true number of infections. Seasonal surveillance in humans primarily captures laboratory-confirmed cases, which may further contribute to reporting delays.


Findings from veterinary surveillance

    From the veterinary perspective, 17 WNV outbreaks among equids and 74 outbreaks among birds have been reported in Europe in 2026. 

    The earliest start date of an outbreak among equids and birds was on 30 March 2026 in France and 31 March 2026 in Italy, while the latest onset of an outbreak among equids and birds was, respectively, on 31 July 2026 in Netherlands and 28 July 2026 in Italy

    Outbreaks among equids have been reported by France (five outbreaks), Greece (five outbreaks), Italy (five outbreaks), the Netherlands (one outbreak) and Spain (one outbreak). 

    Outbreaks among birds have been reported by Italy (64 outbreaks), France (five outbreaks), Spain (three outbreaks), Austria (one outbreak) and Belgium (one outbreak).

    No information was available on the equid species involved in the outbreaks reported in the Animal Disease Information System (ADIS). 

    The bird species most frequently associated with the reported outbreaks were the common magpie (23) and the hooded crow (20), followed by the carrion crow (5), the common kestrel (5), the Eurasian blackbird (5), the yellow-legged gull (3), Adalbert’s eagle (2), the common wood-pigeon (2), and the little owl (2). 

    Single outbreaks were associated with the common loon, the common raven, the European turtle-dove, the golden eagle, the grey heron, the house sparrow and the northern goshawk.

    The monthly number of WNV outbreaks in equids reported during the first part of 2026 was comparable to the corresponding 10-year monthly average (2016−-2025). 

    However, the number of equid outbreaks in July 2026 remained below the levels observed in July 2018, 2024 and 2025, years characterised by particularly high WNV intensity. 

    In contrast, the number of WNV outbreaks in birds slightly exceeded the corresponding four-year monthly average (2022–2025) in April and May, and was substantially higher in June. 

    This trend reversed in July 2026, when the number of reported outbreaks in birds fell below the four-year average, although it remained higher than in July 2025. However, it should be noted that reporting delays may affect the July numbers, as some outbreaks occurring during that month may be notified in August.

    As at 5 August 2026, outbreaks in birds and/or equids have been reported in 43 NUTS 3 regions across seven countries. This compares with 55 regions (10 countries) during the same period in 2025 and 42 regions (eight countries) in 2024. All seven countries reported WNV outbreaks in birds and/or equids in 2025 and in prior years, reflecting endemic WNV activity in these territories. However, as at 5 August, outbreaks in birds and/or equids were reported to ADIS for the first time in the following six regions: by France in Hauts-de-Seine (FR105) and Seine-et-Marne (FR102); by Belgium in Arr. Namur (BE352), by Greece in Drama (EL514), by Italy in Genova (ITC33) and by the Netherlands in Delf en Westland (NL362).


Patterns across human and veterinary surveillance

    Four countries – France, Greece, Italy, and Spain – reported both human WNV infections and outbreaks in equids and/or birds

    As at 5 August, Italy accounted for most of the reported human cases (56.7%) and animal outbreaks (75.8%). 

    Greece reported the second-largest share of human cases (26.5%) but only five equid outbreaks and no bird outbreaks, representing 5.5% of all reported animal outbreaks.

    Differences in the patterns observed across European countries may reflect a combination of ecological, climatic and surveillance-related factors

    Favourable climatic conditions and the presence of ecological hotspots, such as wetlands and agricultural areas, may support mosquito vector populations and influence the distribution and behaviour of animal hosts, thereby facilitating WNV circulation. At the same time, differences in WNV surveillance systems across Europe may affect detection and reporting rates.

    The first indication of WNV activity may arise from either human or animal surveillance, depending on local epidemiology, detection capacity and surveillance system sensitivity. Therefore, the absence of reports from one sector should not be interpreted as evidence that WNV is not circulating. 

    In France (PyrĂ©nĂ©es-Orientales, FRJ15), Greece (Drama, EL514), and Italy (Genova, ITC33), human cases were reported before, or in the absence of, notified outbreaks in birds or equids. 

    Conversely, in Belgium (Arr. Namur, BE352), France (Hauts-de-Seine, FR105 and Seine-et-Marne, FR102) and the Netherlands (Delft en Westland, NL362), animal detections preceded human cases. 

    Belgium is a relevant example, as WNV was first reported in the country in 2025 through avian surveillance, with no previous detections in humans and animals. In 2026, it has again been identified in birds in a previously unaffected region, highlighting the role of avian surveillance in detecting local virus circulation and geographical spread.

    Active mosquito surveillance is also important for the early detection of WNV circulation. However, results on WNV detection in mosquitoes are not included in this report because they are not legally required to be reported at European level, and the available information is therefore scattered and often project-based.


Seasonal outlook

    Given the favourable weather conditions for WNV transmission in Europe, ECDC and EFSA expect further human cases and outbreaks in equids and birds to be reported in the coming weeks. In previous years, transmission has typically peaked in August and September.

    ECDC and EFSA continue to closely monitor the situation in Europe.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/infectious-disease-topics/west-nile-virus-infection/surveillance-and-disease-data/monthly-updates

____

Friday, August 7, 2026

Seasonal #surveillance in #humans in 2026 for West Nile virus in #Europe (#WNV) (ECDC, August 7 '26): 241 cases so far of which 139 in #Italy

 


{Excerpt}

Week 32, 2026Produced on 7 August 2026 at 10:00, based on data submitted up until and including 5 August 2026.


Current situation

    Since the beginning of the 2026 transmission season, and as at 5 August, 59 areas affected by West Nile virus (WNV) have been identified in seven countries across Europe.

    These areas are located in: 

        § Italy (36), 

        § Greece (nine), 

        § Romania (six), 

        § North Macedonia (three), 

        § France (two), 

        § Spain (two) and 

        § Germany (one).

    The seven countries have reported 241 locally acquired human cases of WNV infection: 

        § Italy has reported 139

        § Greece 61

        § Spain 17

        § North Macedonia 13

        § Romania six

        § France four and 

        § Germany one case.

    This week, 10 areas are reported as affected for the first time this season. The affected areas identified as at 5 August 2026 are listed in Table 1 and shown in Map 1 below.

(...)


{WNV Affected Areas - Click on Image to Enlarge}

__


Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Friday, July 31, 2026

Seasonal #surveillance in #humans in 2026 for West Nile virus (#WNV) (ECDC, July 31 '26): 158 cases so far of which 94 from #Italy

 


{Summary}

Week 31, 2026 | Produced on 30 July 2026 at 12:00, based on data submitted up until and including 29 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 29 July, 49 areas affected by West Nile virus (WNV) have been identified in seven countries across Europe.

    ° These areas are located in: 

        § Italy (30), 

        § Greece (eight), 

        § Romania (four), 

        § France (two), 

        § North Macedonia (two), 

        § Spain (two) and 

        § Germany (one).

    ° The seven countries have reported 158 locally acquired human cases of WNV infection: 

        § Italy has reported 94

        § Greece 42

        § North Macedonia seven

        § Spain seven

        § Romania five

        § France two and 

        § Germany one case.

    ° This week, 14 areas are reported as affected for the first time this season. The affected areas identified as at 29 July 2026 are listed in Table 1 and shown in Map 1 below.

(...)


{Click on Image to Enlarge}

__

{In Yellow, areas already affected since the beginning of the season.}

{In Red, areas newly affected this week.}

__

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Friday, July 24, 2026

Seasonal #surveillance in #humans in 2026 for #WNV (West Nile Virus) (ECDC, July 24 '26): 81 confirmed cases so far of which 46 in #Italy

 


{Excerpt}

Week 30, 2026Produced on 23 July 2026 at 09:45, based on data submitted up until and including 22 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 22 July, 35 areas affected by West Nile virus (WNV) have been identified in six countries across Europe.

    ° These areas are located in: 

        § Italy (20), 

        § Greece (six), 

        § Romania (four), 

        § North Macedonia (two), 

        § Spain (two) and 

        § France (one).


    ° The six countries have reported 81 locally acquired human cases of WNV infection: 

        § Italy has reported 46

        § Greece 21

        § North Macedonia five

        § Romania five

        § Spain three and 

        § France one case.


    ° This week, nine areas are reported as affected for the first time this season. The affected areas identified as at 22 July 2026 are listed in Table 1 and shown in Map 1 below.

(...)


Table 1. Areas affected by West Nile virus during the 2026 transmission season at 22 July, by country and NUTS3 or GAUL1 area




{Click on Images to Enlarge}

(...)


____

Monday, July 20, 2026

Excess #mortality attributable to the 2025 #Iberian Peninsula #blackout

 


Abstract

On 28 April 2025, a widespread power outage affected mainland Portugal and Spain for around ten hours, causing major disruptions and eight reported deaths. Health impacts of blackouts range from direct effects, such as medical equipment failure, to indirect effects such as disrupted healthcare. Here we show that the 2025 Iberian blackout is associated with increased mortality in Spain, but not in Portugal. We find little evidence of excess mortality on the day of the event itself. In Spain, however, mortality rises over the next two days (+167 deaths; 95% credible interval: +28 to +300; +2.4% relative increase), particularly among women aged 85+. We also observe regional differences, but their drivers remain uncertain and may include variation in outage severity, underlying vulnerabilities, or local health-system and infrastructure conditions. These findings highlight the underestimated health burden of blackouts and the need for improved preparedness in a changing climate.

Source: 


Link: https://www.nature.com/articles/s41467-026-75581-w

____

Friday, July 17, 2026

#WNV in #humans, the European Region, Weekly #Report (ECDC, July 17 '26): #Italy (21), #Greece (7), North #Macedonia (2), #Romania (2) & #Spain (2) cases so far

 


{Excerpt}

Week 29, 2026Produced on 17 July 2026 at 08:30, based on data submitted up until and including 15 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as at 15 July, 28 areas affected by West Nile virus (WNV) have been identified in five countries across Europe {1}.

    ° These areas are located in: 

        § Italy (17), 

        § Greece (five), 

        § North Macedonia (two), 

       § Romania (two) and 

        § Spain (two).

    ° The five countries have reported 34 locally acquired {2} human cases of WNV infection

        § Italy has reported 21

        § Greece seven,     

        § North Macedonia two

        § Romania two and 

        § Spain two cases.

    ° This week, 17 areas are reported as affected for the first time this season. The affected areas identified as at 15 July 2026 are listed in Table 1 and shown in Map 1 below.

(...)

Table 1. Areas affected by West Nile virus during the 2026 transmission season at 15 July, by country and NUTS3 or GAUL1 area



{Click on Images to Enlarge}

__

* ‘First reported this week’ indicates that the affected area was not included in the previous weekly overview.

(...)

Source: 


____


Thursday, July 16, 2026

#Spain, Ministry of Health is strengthening #prevention, #preparedness and response to #animal-borne #influenza with a national plan (Min. Health, July 16 '26)

 


    Madrid, July 16, 2026.- The Public Health Commission has approved the State Plan against infections by influenza viruses of zoonotic origin: Prevention, Surveillance and Control, which establishes a common framework for prevention, surveillance, early detection and response to influenza viruses that circulate in animals and can be transmitted to people.

    The Plan adopts the "One Health" approach and establishes a joint response across the fields of human health, animal health, and the environment. Its objective is to improve coordination among the different sectors at the national, regional, and local levels, and to ensure that epidemiological, microbiological, and environmental information is integrated, up-to-date, and readily available to facilitate the early implementation of control measures.

    The document has been coordinated by the Center for Coordination of Health Alerts and Emergencies (CCAES) of the Ministry of Health and prepared jointly with the Ministries of Agriculture, Fisheries and Food and for Ecological Transition and the Demographic Challenge, the Carlos III Health Institute, the Spanish Agency for Food Safety and Nutrition and other units involved in the prevention and management of these risks.

    Zoonotic influenza viruses circulate among animals. Transmission to humans remains infrequent and is usually linked to direct contact with infected animals, their secretions, or contaminated environments. However, their ability to mutate and exchange genetic material necessitates continuous surveillance, especially given the increased detection of these viruses in various mammal species.

    The Plan organizes the actions into four scenarios , which allow the measures to be progressively adapted to the epidemiological situation of each territory.

    Scenario 0 corresponds to a situation with no detected infections in animals or people and focuses on ordinary actions of prevention, surveillance, training and maintenance of diagnostic capabilities.

    Scenario 1 is activated upon detection of outbreaks in wild or captive animals. It distinguishes between isolated outbreaks in birds, multiple outbreaks distributed across a territory, and detections in wild mammals.

    Scenario 2 considers outbreaks in domestic animals and also differentiates between isolated outbreaks in birds, multiple outbreaks, and detections in domestic mammals.

    Finally, scenario 3 applies when a human infection is identified. In this case, a distinction is made between cases with known exposure to animals or contaminated environments, those where no risk exposure is identified, and cases associated with contact with another infected person, which would imply possible limited human-to-human transmission.

    The scenarios are not mutually exclusive and may be applied simultaneously in the same territory. Each autonomous community will conduct its own risk assessment to determine the necessary measures in each affected province, community, or geographical area.

    The Plan envisions the creation of a Permanent State Committee for Coordination and Monitoring , chaired and technically coordinated by the CCAES, responsible for reviewing preparedness and response measures, promoting common protocols, conducting joint risk assessments, and evaluating the Plan's effectiveness. Furthermore, it recommends that the autonomous communities establish equivalent bodies to coordinate actions related to public health, animal health, the environment, food safety, and occupational health.

    This body will include representatives from the competent departments in public health, animal health, biodiversity, food safety, occupational health, medicines and health products and epidemiological and microbiological surveillance, as well as from the autonomous communities, the Spanish Federation of Municipalities and Provinces and experts.

    Human health measures focus especially on people who, due to their professional activity, may come into contact with infected animals, their secretions or contaminated materials, such as livestock farm personnel, veterinary professionals, environmental agents or zoo workers.

    Companies must assess the risk, provide the necessary protective equipment, and ensure health monitoring. Occupational risk prevention services will identify and monitor exposed personnel in the event of outbreaks in animals and, where appropriate, may recommend PCR tests, preventive antiviral treatment, or vaccination against zoonotic viruses.

    The Plan also maintains the recommendation for seasonal flu vaccination for those who work in direct contact with animals, with the aim of reducing the risk of coinfection by human and animal flu viruses.

    In the animal sector , the Plan strengthens surveillance of wild and domestic birds and mammals, as well as genomic analysis of viruses to detect changes that could increase their transmissibility. In the event of outbreaks on farms, biosecurity measures, movement controls, confinement, and, where appropriate, vaccination will be implemented.

    In parks and urban or peri-urban areas, protocols will be established to safely remove sick or dead animals, clean and disinfect affected areas, and inform the public. It is recommended not to touch or handle them and to report their presence to the appropriate authorities.

    The Plan incorporates risk communication and community participation as one of its five main components. To this end, an inter-institutional communication group will be established, websites with updated information will be created, and campaigns will be developed targeting both the general public and the professional sectors with the greatest exposure.

    Media and social media will also be monitored to detect and respond to rumors, false content, or unverified information. In higher-risk scenarios, an official spokesperson will be appointed, information will be updated daily, and, when necessary, a citizen hotline will be activated.

    The Permanent State Committee will develop the indicators that will allow the evaluation of preparedness and response, as well as compliance with the Plan in its various components and at the state and regional levels.

    In the last year, more than 150 outbreaks of avian influenza have been detected in Spain, mostly in wild birds, although outbreaks have also been recorded in poultry, leading to the culling of thousands of animals. Despite the increased circulation of the virus among birds, Spain has not registered any human cases of avian influenza to date. Regarding swine influenza, three human cases of infection have been identified in Spain since 2009.

    The new Plan will strengthen prevention, early detection and coordinated response to any changes in the epidemiological situation.

Source: 


Link: https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6965

____

Friday, July 10, 2026

Seasonal #surveillance in #humans in 2026 for #WNV - Update (ECDC, July 10 '26): #Italy reported 6 cases, #Macedonia 2, #Romania 2, #Greece 1, #Spain 1

 


Week 28, 2026Produced on 9 July 2026 at 08:45, based on data submitted up to 8 July 2026.


Current situation

    ° Since the beginning of the 2026 transmission season, and as of 8 July, 11 areas affected by West Nile virus (WNV) have been identified in five countries across Europe {1}.

    ° These areas are located in: 

        - Italy (five), 

        - North Macedonia (two), 

        - Romania (two), 

        - Greece (one) and 

        - Spain (one).

    ° The five countries have reported 12 locally acquired {2} human cases of WNV infection: 

        - Italy has reported six, 

        - North Macedonia two, 

        - Romania two, 

        - Greece one and 

        - Spain one case.

    ° This week, five areas are reported as affected for the first time this season. 

(...)


Table 1. Areas affected by West Nile virus during the 2026 transmission season as of 8 July, by country and NUTS3 or GAUL1 area


{Click on Image to Enlarge}

(...)

__

{*} ‘First reported this week’ indicates that the affected area was not included in the previous weekly overview.

{1} European Union/European Economic Area countries and selected EU-neighbouring countries (Albania, Bosnia and Herzegovina, Kosovo**, Montenegro, North Macedonia, Serbia and TĂ¼rkiye).

{**} This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.↩︎

{2} Cases acquired within the reporting country.↩︎

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/west-nile-fever/surveillance-and-disease-data/disease-data-ecdc

____

Monday, June 22, 2026

#Spain reported a locally acquired Crimean-Congo Hemorrhagic Fever (#CCHF), according latest ECDC report (June 22 '26)

 


(...)

Epidemiological summary

    This is the first report of the weekly seasonal surveillance reports on Crimean-Congo haemorrhagic fever (CCHF) infections in 2026.

    Since the beginning of 2026 and as of 17 June 2026, one country in Europe has reported locally acquired cases of CCHF: 

        ° Spain (one case).

    The case in Salamanca (Spain) is not unexpected as Hyalomma spp. – the main vectors of CCHF virus – are widely distributed across the region. 

    In addition, CCHF virus is known to circulate in local animal populations, and human cases have previously been reported there. 

    The timing of this case aligns with the expected seasonal pattern of CCHF in Spain, and is probably linked to increased tick activity.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/crimean-congo-haemorrhagic-fever/surveillance-and-updates/seasonal

____

Thursday, June 4, 2026

#Spain, Health authorities have established #criteria for #hospital discharge and follow-up for confirmed cases of #hantavirus (June 4 '26)

 


    Madrid, June 4, 2026 

    The Ministry of Health has updated the protocol for managing people affected by the Andes hantavirus outbreak associated with the MV Hondius cruise ship, establishing the clinical and microbiological criteria that will allow hospital discharge of confirmed cases and the conditions for the completion of contact tracing.

    According to the protocol approved by the Public Health Commission, people diagnosed with Andes hantavirus infection who remain admitted to a High Level Isolation and Treatment Unit (UATAN) may be discharged from the hospital once clinical recovery has been achieved, for which they must have remained at least three days without symptoms compatible with the disease and obtain two negative results in PCR tests performed on urine and oropharyngeal exudate, separated by a minimum interval of 48 hours.

    The most recent studies on Andes virus show that viral RNA can be detected in blood for an extended period after clinical recovery. 

    For this reason, discharge criteria are not based solely on a negative blood PCR test, but also on the absence of symptoms and negative results in biological samples most directly related to possible viral shedding, such as urine and oropharyngeal swabs.

    Consequently, the protocol expressly acknowledges that some individuals may continue to test positive for COVID-19 via PCR in their blood after hospital discharge. 

    Available scientific evidence indicates that this persistence of viral genetic material can continue after clinical recovery, without posing a risk of disease transmission. 

    In these cases, they will remain under clinical follow-up for six months to monitor their progress, detect any potential long-term effects, and undergo regular check-ups until the test is negative.

    Those being monitored as contacts must complete the maximum quarantine period established by the protocol. 

    If they remain asymptomatic throughout the home monitoring period, a sample will be taken at the end of this period and analyzed by the National Microbiology Center. 

    Only after obtaining a negative result will they be able to end the monitoring measures and fully resume their normal activities.

    These measures are part of the surveillance and control system designed to ensure the safety of patients, healthcare professionals and the general population, applying the precautionary principle while international monitoring of this outbreak continues.

Source: 


Link: https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6928

____

Monday, June 1, 2026

First reported case of #Andes #hantavirus cardiopulmonary syndrome treated with a combination of #favipiravir, #ribavirin, icatibant and baricitinib

 

ABSTRACT

Objectives

To describe the first documented case of Andes virus (ANDV) hantavirus cardiopulmonary syndrome (HCPS) in Spain and the first worldwide use of a therapeutic regime including two antivirals (favipiravir and ribavirin) and two host-directed drugs (baricitinib and icatibant).

Methods

A 69-year-old Spanish man, repatriated following a multinational ANDV outbreak aboard a cruise ship, was managed in a high-level isolation unit. Diagnosis was established by RT-PCR and serology while he was still asymptomatic as part of protocol-driven screening. Under compassionate-use authorisation and written informed consent, the patient received ribavirin (initially intravenous, then switched to oral on day +4), oral favipiravir, subcutaneous icatibant, and oral baricitinib, with serial clinical, laboratory, and radiological monitoring.

Results

Hypoxaemia, bilateral B-lines, thrombocytopenia, lymphopenia, and hyponatraemia developed within 24 hours after diagnosis. The combination regimen was initiated on day 0, and baricitinib was added on day +1, coinciding with the need for high-flow nasal oxygen. Sustained clinical, laboratory, and radiological recovery occurred from day +2 onwards, without progression to invasive ventilation or vasopressors. Mild diarrhoea attributed to ribavirin led to its discontinuation on day +5, shortly after the IV-to-oral switch. Severe recurrent diarrhoea on day +8, attributed to favipiravir, prompted its withdrawal before completion of the planned 10-day course; baricitinib was completed on day +10.

Conclusions

This sentinel case of imported HCPS in non-endemic Europe was managed with, to our knowledge, the first reported combined antiviral and host-directed regimen for this syndrome and the first reported use of favipiravir in a patient with hantavirus infection. The favourable outcome supports prospective evaluation of antiviral combinations and adjunctive immunomodulation within international preparedness protocols.

Source: 


Link: https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(26)00310-1/fulltext

____

Tuesday, May 26, 2026

#Zoonotic #infections and genomic #evolution associated with novel #reassortants swine-origin #influenza A viruses in #Spain

 


Abstract

Influenza A virus (IAV) circulates widely in European pig populations and continues to diversify through frequent introductions from humans, followed by reassortment within swine. Spain represents a particularly dynamic ecological setting due to the coexistence of intensive white pig production, extensive Iberian pig systems, and abundant wild boar populations. This study provides an integrated analysis of IAV evolution and genomic diversity in swine in Spain between 2019 and 2022, expanding on previous surveillance from 2016 to 2019. Sampling across 24 provinces yielded 66 new whole genome sequences from Iberian and white pigs. We identified 18 genotypes, including 11 novel reassortants not detected in our previous survey. Several genotypes, such as H1huN2 G21 and G22, H3N2 G23, and the unusual H3N1 G12, were exclusive to the country. Some genotypes were detected across white pigs, Iberian pigs, and wild boar in Toledo and Badajoz, suggesting viral flow among swine populations. Phylogenetic analyses revealed ongoing introductions of H1N1pdm09 from humans into pigs, generating at least five reassortant genotypes (G10, G16 to G19). These lineages incorporated pandemic internal cassettes and, in some cases, human seasonal N2 segments, highlighting the continued role of humans as a source of viral incursions. Conversely, four zoonotic infections (H1N1v) detected in Spain between 2022 and 2026 were linked to genotypes circulating in white pigs, underscoring the bidirectional nature of IAV transmission at the human swine interface. Overall, this study demonstrates that Spain provides ecological conditions conducive to IAV diversification, reassortment, and zoonotic risk. The findings reinforce the need for sustained One Health surveillance.


Competing Interest Statement

The A.G.-S. laboratory has received research support from Avimex, Dynavax, Pharmamar, and Accurius, outside of the reported work within the last three years. A.G.-S. has consulting agreements for the following companies involving cash and/or stock within the last three years: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, Avimex, Pagoda, Accurius, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Virofend and Prosetta, outside of the reported work. A.G.-S. has been an invited speaker in meeting events within the last three years organized by Seqirus, Novavax and Hipra. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work. The rest of the authors report no conflicts of interest.


Funder Information Declared

Centre for Research on Influenza Pathogenesis and Transmission (CRIPT), one of the National Institute of Allergy and Infectious Diseases (NIAID) funded Centres of Excellence for Influenza Research and Response (CEIRR), contract #75N93021C00014

Intramural Research Program of the National Library of Medicine at the US National Institutes of Health

Source: 


____

My New Space

Most Popular Posts